Your browser doesn't support javascript.
loading
Toenail zinc and risk of prostate cancer in the MCC-Spain case-control study.
Gutiérrez-González, Enrique; Pastor-Barriuso, Roberto; Castelló, Adela; Castaño-Vinyals, Gemma; Fernández de Larrea-Baz, Nerea; Dierssen-Sotos, Trinidad; Jiménez-Moleón, José Juan; Molina-Barceló, Ana; Fernández-Tardón, Guillermo; Zumel-Marne, Ángela; Moreno, Víctor; Gómez-Ariza, José Luis; Sierra, M Ángeles; García-Barrera, Tamara; Espinosa, Ana; Plans-Beriso, Elena; Gómez-Acebo, Inés; Aragonés, Nuria; Kogevinas, Manolis; Pollán, Marina; Pérez-Gómez, Beatriz.
Affiliation
  • Gutiérrez-González E; General Directorate of Public Health, Ministry of Health, Paseo Del Prado 18-20, 28014, Madrid, Spain.
  • Pastor-Barriuso R; Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain.
  • Castelló A; Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain.
  • Castaño-Vinyals G; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Barcelona Institute of Global Health (ISGlobal), Carrer Del Dr. Aiguader, 88, 08003, Barcelona, Spain; University Pompeu Fabra, Plaça de La Mercè, 10-12, 08002, Barcelona, Spai
  • Fernández de Larrea-Baz N; Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain.
  • Dierssen-Sotos T; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Department of Medical and Surgical Sciences, Faculty of Medicine, University of Cantabria-IDIVAL, Calle Cardenal Herrera Oria, 39011, Santander, Spain.
  • Jiménez-Moleón JJ; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Department of Preventive Medicine and Public Health, University of Granada, Av. de La Investigación, 11, 18016, Granada, Spain; Institute of Health Research IBS., Granada, Spai
  • Molina-Barceló A; Cancer and Public Health Area, The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Av. de Catalunya, 21, 46020, Valencia, Spain.
  • Fernández-Tardón G; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Health Research Institute of Asturias (ISPA), University of Oviedo, Av. Del Hospital Universitario, 33011, Oviedo, Spain.
  • Zumel-Marne Á; Research Centre for Natural Resources, Health and the Environment, University of Huelva, C/ Menéndez Pelayo, 21002, Huelva, Spain; Servei Cirurgia Ortopèdica i Traumatologia. Althaia Xarxa Assistencial Universitària de Manresa, 08243 Manresa, España; Public Health Research Group, University of Alica
  • Moreno V; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Avinguda de La Granvia de L'Hospitalet, 199-203, 08908, L'Hospitalet de Llobregat, Barcelona, Spain; Color
  • Gómez-Ariza JL; Research Centre for Natural Resources, Health and the Environment, University of Huelva, C/ Menéndez Pelayo, 21002, Huelva, Spain; Department of Chemistry, Faculty of Experimental Sciences, Campus El Carmen, University of Huelva, C/ Menéndez Pelayo, 21002, Huelva, Spain.
  • Sierra MÁ; Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain.
  • García-Barrera T; Research Centre for Natural Resources, Health and the Environment, University of Huelva, C/ Menéndez Pelayo, 21002, Huelva, Spain; Department of Chemistry, Faculty of Experimental Sciences, Campus El Carmen, University of Huelva, C/ Menéndez Pelayo, 21002, Huelva, Spain.
  • Espinosa A; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Barcelona Institute of Global Health (ISGlobal), Carrer Del Dr. Aiguader, 88, 08003, Barcelona, Spain; University Pompeu Fabra, Plaça de La Mercè, 10-12, 08002, Barcelona, Spai
  • Plans-Beriso E; Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain.
  • Gómez-Acebo I; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Department of Medical and Surgical Sciences, Faculty of Medicine, University of Cantabria-IDIVAL, Calle Cardenal Herrera Oria, 39011, Santander, Spain.
  • Aragonés N; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Cancer Surveillance and Registry Unit, Division of Public Health, Department of Health, C. San Martín de Porres, 6, 28035, Madrid, Spain.
  • Kogevinas M; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain; Barcelona Institute of Global Health (ISGlobal), Carrer Del Dr. Aiguader, 88, 08003, Barcelona, Spain; University Pompeu Fabra, Plaça de La Mercè, 10-12, 08002, Barcelona, Spai
  • Pollán M; Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain.
  • Pérez-Gómez B; Department of Epidemiology of Chronic Diseases, National Centre for Epidemiology, Institute of Health Carlos III, Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Monforte de Lemos 5, 28029, Madrid, Spain. Electronic address:
Environ Res ; 245: 118065, 2024 Mar 15.
Article in En | MEDLINE | ID: mdl-38159663
ABSTRACT

BACKGROUND:

Some researchers have suggested that zinc (Zn) could reduce the risk of prostate cancer (PC). However, research from observational studies on the relationship between PC risk and biomarkers of Zn exposure shows conflicting results.

OBJECTIVES:

To evaluate the association between toenail Zn and PC, considering tumour extension and aggressiveness, along with a gene-environment approach, exploring the interaction of individual genetic susceptibility to PC in the relationship between toenail Zn and PC.

METHODS:

In MCC-Spain study we invited all incident PC cases diagnosed in the study period (2008-2013) and recruited randomly selected general population controls. In this report we included 913 cases and 1198 controls with toenail Zn determined by inductively coupled plasma mass spectrometry. To measure individual genetic susceptibility, we constructed a polygenic risk score based on known PC-related single nucleotide polymorphisms. The association between toenail Zn and PC was explored with mixed logistic and multinomial regression models.

RESULTS:

Men with higher toenail Zn had higher risk of PC (OR quartile 4 vs.1 1.41; 95% CI 1.07-1.85). This association was slightly higher in high-grade PC [(ISUP≤2 Relative risk ratio (RRR) quartile 4 vs.1 1.36; 1.01-1.83) vs. (ISUP3-5 RRR quartile 4 vs.1 1.64; 1.06-2.54)] and in advanced tumours [(cT1-cT2a RRR quartile 4 vs.1 1.40; 95% CI 1.05-1.89) vs. (cT2b-cT4 RRR quartile 4 vs.1 1.59; 1.00-2.53)]. Men with lower genetic susceptibility to PC were those at higher risk of PC associated with high toenail Zn (OR quartile 4 vs.1 2.18; 95% CI 1.08-4.40).

DISCUSSION:

High toenail Zn levels were related to a higher risk for PC, especially for more aggressive or advanced tumours. This effect was stronger among men with a lower genetic susceptibility to PC.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Zinc Limits: Humans / Male Country/Region as subject: Europa Language: En Journal: Environ Res Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Zinc Limits: Humans / Male Country/Region as subject: Europa Language: En Journal: Environ Res Year: 2024 Document type: Article Affiliation country:
...